

Joshua M Sharfstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7198672/publications.pdf>

Version: 2024-02-01

149
papers

2,736
citations

279487

23
h-index

223531

46
g-index

149
all docs

149
docs citations

149
times ranked

3765
citing authors

#	ARTICLE	IF	CITATIONS
1	Confronting the Stigma of Opioid Use Disorder and Its Treatment. JAMA - Journal of the American Medical Association, 2014, 311, 1393.	3.8	244
2	Diagnostic Testing for the Novel Coronavirus. JAMA - Journal of the American Medical Association, 2020, 323, 1437.	3.8	209
3	A Systemic Approach to Containing Health Care Spending. New England Journal of Medicine, 2012, 367, 949-954.	13.9	155
4	Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration. New England Journal of Medicine, 2010, 363, 1489-1491.	13.9	136
5	Over the Counter but No Longer under the Radar Pediatric Cough and Cold Medications. New England Journal of Medicine, 2007, 357, 2321-2324.	13.9	134
6	Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Lancet, The, 2021, 398, 2186-2192.	6.3	106
7	Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers Within the Treatment System. NAM Perspectives, 2020, 2020, .	1.3	90
8	Maryland's All-Payer Approach to Delivery-System Reform. New England Journal of Medicine, 2014, 370, 493-495.	13.9	85
9	A Bold Response to the COVID-19 Pandemic. JAMA - Journal of the American Medical Association, 2020, 323, 1790-1791.	3.8	80
10	The FDA as a Public Health Agency. New England Journal of Medicine, 2009, 360, 2493-2495.	13.9	66
11	The Urgency and Challenge of Opening K-12 Schools in the Fall of 2020. JAMA - Journal of the American Medical Association, 2020, 324, 133.	3.8	61
12	Tobacco Product Regulation A Public Health Approach. New England Journal of Medicine, 2010, 362, 1753-1756.	13.9	60
13	Attacks on Public Health Officials During COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 741.	3.8	58
14	Achieving Health Equity by Design. JAMA - Journal of the American Medical Association, 2015, 313, 1417.	3.8	54
15	Maryland's Global Hospital Budgets Preliminary Results from an All-Payer Model. New England Journal of Medicine, 2015, 373, 1899-1901.	13.9	53
16	Uncoupling vaccination from politics: a call to action. Lancet, The, 2021, 398, 1211-1212.	6.3	53
17	The Pandemic and the Supply Chain: Gaps in Pharmaceutical Production and Distribution. American Journal of Public Health, 2021, 111, 635-639.	1.5	34
18	Transparency at the Food and Drug Administration. New England Journal of Medicine, 2010, 362, 2341-2343.	13.9	33

#	ARTICLE	IF	CITATIONS
19	FDA Regulation of Laboratory-Developed Diagnostic Tests. JAMA - Journal of the American Medical Association, 2015, 313, 667.	3.8	31
20	Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products. JAMA - Journal of the American Medical Association, 2019, 321, 676.	3.8	30
21	Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the USA. Lancet, The, 2022, 400, 535-538.	6.3	27
22	Campaign Contributions from the American Medical Political Action Committee to Members of Congress – For or Against the Public Health?. New England Journal of Medicine, 1994, 330, 32-37.	13.9	26
23	Marketing Claims for Infant Formula. JAMA Pediatrics, 2017, 171, 105.	3.3	26
24	Global Budgets in Maryland. JAMA - Journal of the American Medical Association, 2018, 319, 2475.	3.8	25
25	Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration. JAMA Internal Medicine, 2020, 180, 301.	2.6	25
26	Announcing the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Lancet, The, 2021, 397, 1165-1167.	6.3	25
27	Chronic Pain, Addiction, and Zohydro. New England Journal of Medicine, 2014, 370, 2061-2063.	13.9	24
28	Facilitating Methadone Use in Hospitals and Skilled Nursing Facilities. JAMA Internal Medicine, 2020, 180, 7.	2.6	24
29	The Strange Journey of Population Health. Milbank Quarterly, 2014, 92, 640-643.	2.1	23
30	Role of the FDA in Affordability of Off-Patent Pharmaceuticals. JAMA - Journal of the American Medical Association, 2016, 315, 461.	3.8	22
31	Making Amends for the Opioid Epidemic. JAMA - Journal of the American Medical Association, 2019, 321, 1446.	3.8	21
32	Reassuring the Public and Clinical Community About the Scientific Review and Approval of a COVID-19 Vaccine. JAMA - Journal of the American Medical Association, 2020, 324, 1296.	3.8	21
33	Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine. JAMA - Journal of the American Medical Association, 2021, 325, 2445.	3.8	20
34	Analysis of Ingredients of Supplements in the National Institutes of Health Supplement Database Marketed as Containing a Novel Alternative to Anabolic Steroids. JAMA Network Open, 2020, 3, e202818.	2.8	19
35	Private Equity and Dermatology – “First, Do No Harm. JAMA Dermatology, 2019, 155, 1007.	2.0	18
36	Enhancing Community Engagement by Schools and Programs of Public Health in the United States. Annual Review of Public Health, 2021, 42, 405-421.	7.6	18

#	ARTICLE	IF	CITATIONS
37	Fungal Meningitis From Injection of Contaminated Steroids. JAMA - Journal of the American Medical Association, 2012, 308, 2461.	3.8	17
38	An Update on Maryland's All-Payer Approach to Reforming the Delivery of Health Care. JAMA Internal Medicine, 2015, 175, 1083.	2.6	17
39	Breaking the gridlock: Regulation of dietary supplements in the United States. Drug Testing and Analysis, 2016, 8, 424-430.	1.6	17
40	Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion. JAMA - Journal of the American Medical Association, 2016, 315, 984.	3.8	17
41	Incentives for COVID-19 vaccination. The Lancet Regional Health Americas, 2022, 8, 100205.	1.5	17
42	Lessons Learned From the Opioid Epidemic. JAMA - Journal of the American Medical Association, 2019, 322, 809.	3.8	16
43	Long-Acting Cabotegravir for HIV Prevention. JAMA - Journal of the American Medical Association, 2022, 327, 921.	3.8	16
44	The Opportunity of CBD "Reforming the Law. New England Journal of Medicine, 2019, 381, 297-299.	13.9	15
45	The Patchwork U.S. Public Health System. New England Journal of Medicine, 2022, 386, 1-4.	13.9	15
46	Comparison of US County-Level Public Health Performance Rankings With County Cluster and National Rankings. JAMA Network Open, 2019, 2, e186816.	2.8	14
47	Identifying and Tracking SARS-CoV-2 Variants "A Challenge and an Opportunity. New England Journal of Medicine, 2021, 385, 389-391.	13.9	14
48	On Fear, Distrust, and Ebola. JAMA - Journal of the American Medical Association, 2015, 313, 784.	3.8	13
49	Global Budgets for Rural Hospitals. Milbank Quarterly, 2016, 94, 255-259.	2.1	13
50	Population Health Case Reports. JAMA - Journal of the American Medical Association, 2016, 315, 2663.	3.8	13
51	Unrest in Baltimore. JAMA - Journal of the American Medical Association, 2015, 313, 2425.	3.8	12
52	The Adequacy of Individual Hospital Data to Identify High Utilizers and Assess Community Health. JAMA Internal Medicine, 2016, 176, 856.	2.6	12
53	Banishing "Stakeholders". Milbank Quarterly, 2016, 94, 476-479.	2.1	12
54	Enhancing Transparency at the US Food and Drug Administration. JAMA - Journal of the American Medical Association, 2017, 317, 1621.	3.8	12

#	ARTICLE	IF	CITATIONS
55	Innovation and Entrepreneurship: Harnessing the Public Health Skill Set in a New Era of Health Reforms and Investment. <i>Journal of Public Health Management and Practice</i> , 2018, 24, 99-101.	0.7	12
56	Something new in the air: Paying for community-based environmental approaches to asthma prevention and control. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1244-1249.	1.5	11
57	Vaccines and the Trump Administration. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1305.	3.8	11
58	Unexpected Health Insurance Profits and the COVID-19 Crisis. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1713.	3.8	11
59	Battling Falsehoods in the COVID-19 Pandemic. <i>JAMA Health Forum</i> , 2022, 3, e221587.	1.0	11
60	Toward Innovative Models of Health Care and Financing. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1261.	3.8	9
61	Working with Communities to Achieve Health Equity in Maryland's Five Health Enterprise Zones. <i>Journal of Health Care for the Poor and Underserved</i> , 2014, 25, 4-10.	0.4	9
62	A Stronger Treatment System for Opioid Use Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2165.	3.8	9
63	Relationship Between the American Academy of Pediatrics and Infant Formula Companies. <i>JAMA Pediatrics</i> , 2017, 171, 613.	3.3	9
64	Maryland's All-Payer Health Reform—A Promising Work in Progress. <i>JAMA Internal Medicine</i> , 2018, 178, 269.	2.6	9
65	Using Health Care Data to Track and Improve Public Health. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2012.	3.8	8
66	A Spotlight on Sunscreen Regulation. <i>New England Journal of Medicine</i> , 2015, 373, 101-103.	13.9	8
67	The Promotion of Medical Products in the 21st Century. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1795.	3.8	8
68	The COVID-19 Pandemic: An Opportunity to Transform Higher Education in Public Health. <i>Public Health Reports</i> , 2021, 136, 23-26.	1.3	8
69	The evidence and acceptability of taxes on unhealthy foods. <i>Israel Journal of Health Policy Research</i> , 2018, 7, 68.	1.4	8
70	Development of Maryland Local Overdose Fatality Review Teams. <i>Health Promotion Practice</i> , 2016, 17, 596-600.	0.9	7
71	Global Budgets for Safety-Net Hospitals. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1759.	3.8	7
72	Power Morcellators, Postmarketing Surveillance, and the US Food and Drug Administration. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 325.	3.8	7

#	ARTICLE	IF	CITATIONS
73	How the FDA should protect its integrity from politics. <i>Nature</i> , 2020, 585, 161-161.	13.7	7
74	State Leadership in Health Care Transformation. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 349.	3.8	6
75	The Safety of Prescription Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 233.	3.8	6
76	The Opioid Crisis From Research to Practice. <i>Milbank Quarterly</i> , 2017, 95, 24-27.	2.1	6
77	A New Year's Wish on Opioids. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 537.	3.8	6
78	Evaluating the centralized purchasing policy for the treatment of hepatitis C: The Colombian CASE. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00552.	1.1	6
79	Help Is on the Way: Medicare Coverage of Opioid Treatment Programs. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 637-640.	1.3	6
80	What the American Rescue Plan Means for Health Equity. <i>JAMA Health Forum</i> , 2021, 2, e210658.	1.0	6
81	The FDA Safety and Innovation Act. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1437.	3.8	5
82	Promise and Peril for Generic Drugs. <i>JAMA Internal Medicine</i> , 2016, 176, 733.	2.6	5
83	Emergency Department Utilization Among the Uninsured During Insurance Expansion in Maryland. <i>Annals of Emergency Medicine</i> , 2018, 72, 156-165.	0.3	5
84	Performance and Priorities: A Cross-sectional Study of Local Health Department Approaches to Essential Public Health Services. <i>Public Health Reports</i> , 2020, 135, 97-106.	1.3	5
85	Reform at the FDA—In Need of Reform. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 123.	3.8	5
86	The US Regulatory System and COVID-19 Vaccines. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1153.	3.8	5
87	Neurology and the Affordable Care Act. <i>JAMA Neurology</i> , 2015, 72, 623.	4.5	4
88	Pharmaceuticals and Public Health. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2083.	3.8	4
89	Science and the Trump Administration. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1312.	3.8	4
90	How Not to Spend an Opioid Settlement. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1031.	3.8	4

#	ARTICLE	IF	CITATIONS
91	A cross-sectional analysis of trends in dermatology practice size in the United States from 2012 to 2020. Archives of Dermatological Research, 2023, 315, 223-229.	1.1	4
92	Phenytoin Dosage. Pediatrics, 1998, 102, 1223-1223.	1.0	3
93	The FDAâ€™s A Misunderstood Agency. JAMA - Journal of the American Medical Association, 2011, 306, 1250.	3.8	3
94	New Incentive-Based Programs. JAMA - Journal of the American Medical Association, 2013, 310, 259.	3.8	3
95	Improving Medical Device Regulation. JAMA Internal Medicine, 2014, 174, 1779.	2.6	3
96	Accountability for Health. Milbank Quarterly, 2015, 93, 675-678.	2.1	3
97	Resilience in Health Care Financing. JAMA - Journal of the American Medical Association, 2020, 324, 126.	3.8	3
98	Critical Drugs for Critical Care: Protecting the US Pharmaceutical Supply in a Time of Crisis. American Journal of Public Health, 2020, 110, 1346-1347.	1.5	3
99	Affording Genetic Therapies in the Medicaid Program. JAMA Pediatrics, 2020, 174, 523.	3.3	3
100	â€œThis Level of Death, Itâ€™s Newâ€œ Health Care Workers in Their Own Words. JAMA - Journal of the American Medical Association, 2021, 325, 331.	3.8	3
101	US Suicide Rates and Impact of Major Disasters Over the Last Century. primary care companion for CNS disorders, The, 2022, 24, .	0.2	3
102	Dear Health Care Lobbyists . . . Milbank Quarterly, 2015, 93, 15-18.	2.1	2
103	Electronic Cigarettes: Gateway to Understanding the FDA?. Milbank Quarterly, 2015, 93, 251-254.	2.1	2
104	Of Mouse and Measles. JAMA - Journal of the American Medical Association, 2015, 313, 1504.	3.8	2
105	Rethinking Science and Politics. Milbank Quarterly, 2016, 94, 39-42.	2.1	2
106	US Hospital Awards and Community Health Improvement. American Journal of Public Health, 2017, 107, 1076-1077.	1.5	2
107	Hospital Accreditation and Community Health. American Journal of Medicine, 2017, 130, 117-118.	0.6	2
108	Commentary on â€˜Revisiting the â€˜paradigm shiftâ€™ in opioid use: Developments and implications 10 years laterâ€™. Drug and Alcohol Review, 2018, 37, S206-S207.	1.1	2

#	ARTICLE	IF	CITATIONS
109	Public Health Rising to the Challenge: The Bloomberg American Health Initiative. Public Health Reports, 2018, 133, 3S-4S.	1.3	2
110	The Role of Evidence in the US Response to the Opioid Crisis. Epidemiologic Reviews, 2020, 42, 167-170.	1.3	2
111	Additional Barriers to Methadone Use in Hospitals and Skilled Nursing Facilitiesâ€”Reply. JAMA Internal Medicine, 2020, 180, 615.	2.6	2
112	Extreme Risk Protection Ordersâ€”A Tool for Clinicians to Prevent Gun Violence. JAMA Health Forum, 2021, 2, e210948.	1.0	2
113	Child Health Policy and the COVID-19 Pandemic. JAMA Health Forum, 2021, 2, e212921.	1.0	2
114	Unexpected Health Insurance Profits and the COVID-19 Crisis. JAMA Health Forum, 2020, 1, e201094.	1.0	2
115	US Healthcare Policy and Child Poverty. Academic Pediatrics, 2021, 21, S88-S89.	1.0	2
116	Product Approval and Public Health at the US Food and Drug Administration. JAMA - Journal of the American Medical Association, 2021, 326, 2469.	3.8	2
117	The cost of the opioid epidemic, in context. American Journal of Managed Care, 2019, 25, S241-S242.	0.8	2
118	The Development and Implementation of a New Hospital Performance Measure to Assess Hospital Contributions to Community Health and Equity. Health Services Research, 0, , .	1.0	2
119	Kids First?. International Journal of Health Services, 2000, 30, 763-769.	1.2	1
120	Child health initiatives and journal narrow-mindedness. Lancet, The, 2000, 356, 1626.	6.3	1
121	Critical Issues in US Health Care. JAMA - Journal of the American Medical Association, 2013, 310, 1945.	3.8	1
122	Health Care and Poverty. JAMA - Journal of the American Medical Association, 2014, 312, 2200.	3.8	1
123	Treatment for Opioid Use Disorderâ€”Reply. JAMA - Journal of the American Medical Association, 2014, 312, 751.	3.8	1
124	Public Health and the First Amendment. Milbank Quarterly, 2015, 93, 459-462.	2.1	1
125	Violent Injury as a Preventable Condition. Milbank Quarterly, 2016, 94, 708-711.	2.1	1
126	DÃ©jÃ Vu at the FDA. Milbank Quarterly, 2017, 95, 245-248.	2.1	1

#	ARTICLE	IF	CITATIONS
127	Public Health Bundles. <i>Milbank Quarterly</i> , 2017, 95, 474-477.	2.1	1
128	Maryland's Hospital Global Budget Program"Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2040.	3.8	1
129	How Do You Solve a Problem Like Juul?. <i>Milbank Quarterly</i> , 2018, 96, 417-420.	2.1	1
130	Rethinking Payment and Incentives for a Healthy Early Childhood. <i>Academic Pediatrics</i> , 2021, 21, 225-227.	1.0	1
131	Assessment of Public Opinion on Transparency at the US Food and Drug Administration. <i>JAMA Network Open</i> , 2022, 5, e220026.	2.8	1
132	On Working for Henry Waxman. <i>Milbank Quarterly</i> , 2014, 92, 186-190.	2.1	0
133	Speaking With Doctors in Restaurants. <i>Milbank Quarterly</i> , 2014, 92, 422-425.	2.1	0
134	Marketing Claims for Infant Formula Additives and Infant Formula"Reply. <i>JAMA Pediatrics</i> , 2017, 171, 811.	3.3	0
135	Common Ground on Responsibility for Health. <i>Milbank Quarterly</i> , 2017, 95, 718-721.	2.1	0
136	A Health Policy Sonnet. <i>Milbank Quarterly</i> , 2018, 96, 9-12.	2.1	0
137	The Fires Are Burning. <i>Milbank Quarterly</i> , 2018, 96, 623-626.	2.1	0
138	Common Ground on Health. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2518.	3.8	0
139	Crises and Population Health. <i>Milbank Quarterly</i> , 2018, 96, 223-226.	2.1	0
140	Adolescence: An Opportunity for Population Health. <i>Milbank Quarterly</i> , 2019, 97, 926-929.	2.1	0
141	Introduction: State Innovation Models. <i>Milbank Quarterly</i> , 2019, 97, 505-505.	2.1	0
142	The Promise"and Politics"of State Innovation for Health. <i>Milbank Quarterly</i> , 2019, 97, 387-390.	2.1	0
143	Public Opinion on the Sale of Crib Bumpers. <i>JAMA Network Open</i> , 2020, 3, e208089.	2.8	0
144	Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program"Reply. <i>JAMA Internal Medicine</i> , 2020, 180, 916.	2.6	0

#	ARTICLE	IF	CITATIONS
145	Resilience in Health Care Financing. JAMA Health Forum, 2020, 1, e200614.	1.0	0
146	“This Level of Death, It’s New” Health Care Workers in Their Own Words. JAMA Health Forum, 2020, 1, e201551.	1.0	0
147	How Not to Spend an Opioid Settlement. JAMA Health Forum, 2020, 1, e200025.	1.0	0
148	Sharing the Media Spotlight” Communicating About Medical Products in Development During the Pandemic. JAMA Health Forum, 2022, 3, e215246.	1.0	0
149	Global Compassionate Use” A New Lens on a Long-standing Inequity. JAMA Health Forum, 2022, 3, e220500.	1.0	0